



## Supplementary Materials: Expression of Neural Crest Markers GLDC and ERRF1 is Correlated with Melanoma Prognosis


Katharina Jäger, Lionel Larribère, Huizi Wu, Christel Weiss, Christoffer Gebhardt and Jochen Utikal




**Figure S1.** IHC score of short-term survival and long-term survival. IHC score analyses of the two subgroups (short-term survival and long-term survival) are displayed in this chart. Y-axis shows the overall IHC score (0–12), which was calculated as the product of quantity and intensity of the staining. Displayed antibodies did not show significant difference.



**Figure S2.** IHC score in high-risk group A and high-risk group B. IHC score analyses of the two subgroups (high-risk group A and high-risk group B) are displayed in this chart. Y-axis shows the overall IHC score (0–12), which was calculated as the product of quantity and intensity of the staining (not significant).



**Figure S3.** Intensity of TMA stainings. Immunohistochemical stainings are shown for survival group (CD271, GLDC, and ERRFI1) in S100-β-positive melanoma cells. Samples with, mild, moderate, and strong intensity (12× and 80× magnifications) are shown.



**Figure S4.** Intensity of TMA stainings. Immunohistochemical stainings with mild, moderate, and strong intensity are shown for Anti-MSX1, Anti-TWIST, Anti-TNFRSF12a, Anti-IGFBP2, Anti-TNFRSF21, and Anti-PTPRF in S100-β-positive sections (12× and 80× magnifications are shown).

